SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (362)2/26/2003 11:34:46 AM
From: keokalani'nui  Read Replies (1) of 631
 
Morphosys is to issue 588,160 shares to CAT and 363,466 to XOMA this quarter. There were 3,889,944 c/s outstanding at YE.

CAT's interest would be 12.15% after all shares issued.

From Morph's annual report:

Also in 2002, MorphoSys signed a licensing agreement with XOMA and CAT. Under the XOMA licensing agreement the Supervisory Board resolved in October 2002 to issue 363,466 shares to XOMA as a capital increase against contribution in kind. In December 2002, MorphoSys signed a settlement with CAT to resolve longstanding patent litigation issues. As part of the agreement MorphoSys will issue to CAT 588,160 MorphoSys shares as partial consideration for the CAT license. Both the XOMA and CAT share issuances are expected to take place in 2003, and are subject to registration in the commercial register. The respective share issuances exclude shareholders preemptive rights as allowed under the Company’s articles of association.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News